Baiotei: Net profit will be a loss of 336 million yuan in 2025.

Baiotai released its performance report, achieving an operating income of 934 million yuan in 2025, a year-on-year increase of 25.64%; a net loss of 336 million yuan, a decrease from the 510 million yuan loss in the same period last year. During the reporting period, the company actively expanded its market, with sales of adalimumab injection and tocilizumab injection steadily increasing compared to the same period last year. In this reporting period, the company's ustekinumab injection was launched and sold in the United States, leading to growth in licensing and sales revenue.